Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.49 |
| ▸ | DRD3 | P35462 | 10/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD5 | P21918 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923214 | 0.84 | DRD2 (0.47) | DRD2DRD3DRD4DRD5HTR1A | |
| SCHEMBL6928838 | 0.82 | DRD2 (0.48) | DRD2DRD3HTR1AHTR7KCNH2 | |
| SCHEMBL6928842 | 0.81 | DRD2 (0.47) | DRD2DRD3HTR1AHTR7KCNH2 | |
| SCHEMBL21590355 | 0.73 | DRD2 (0.64) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL22444937 | 0.71 | DRD2 (0.60) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6925552 | 0.70 | DRD2 (0.50) | DRD2DRD3DRD4HTR1AHTR7 | |
| SCHEMBL2783496 | 0.70 | DRD2 (0.64) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6220602 | 0.69 | DRD2 (0.57) | DRD2DRD3DRD4HTR1AHTR7 | |
| SCHEMBL4096013 | 0.69 | DRD2 (0.64) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6223873 | 0.69 | DRD2 (0.59) | DRD2DRD3DRD4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | H. LUNDBECK A/S (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6514993-B1 | Useful in the treatment of certain psychic and neurologic disorders | H. LUNDBECK A/S (DK) | 2003-02-04 | — | — | US | disclosed |
| EP-0770066-B1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2000-05-17 | — | — | EP | disclosed |
| EP-0770066-A1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1997-05-02 | — | — | EP | disclosed |
| WO-1995033729-A1 | SEROTONIN 5-HT1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | HTR5A, HTR2C, HTR1D | DRD2 7/4885DRD3 17/4885DRD1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.